The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Taiwan Semiconductor Manufacturing Company evacuated one of its new chip factory construction sites in Kaohsiung, Taiwan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback